Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) is a clinical-stage biopharmaceutical company developing product candidates designed to precisely target proteins critical to immune cell maturation and function. The company's proprietary approach focuses on modulating immune responses to address immune-mediated diseases,… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Corvus Pharmaceuticals, Inc. does
In the company’s own words
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) is a clinical-stage biopharmaceutical company developing product candidates designed to precisely target proteins critical to immune cell maturation and function. The company's proprietary approach focuses on modulating immune responses to address immune-mediated diseases, inflammatory diseases, and cancers.
The company's lead product candidate, soquelitinib, is a selective, orally bioavailable covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), an enzyme involved in T cell signaling and differentiation. Soquelitinib is currently in Phase 3 clinical development for relapsed peripheral T cell lymphoma and Phase 2 development for atopic dermatitis. The company's second product candidate, ciforadenant, is an oral small molecule antagonist of the A2A receptor for adenosine designed to disable tumors' ability to evade immune system attack. Ciforadenant is being evaluated in a Phase 1b/2 clinical trial for metastatic renal cell carcinoma in combination with immunotherapy agents. The company's third product candidate, mupadolimab, is a humanized monoclonal antibody targeting CD73 intended for cancer and infectious disease treatment.
Corvus Pharmaceuticals operates without its own manufacturing facilities, relying instead on third-party contract manufacturers for production of drug candidates for clinical testing and potential commercialization. This strategy allows the company to maintain efficient infrastructure while focusing expertise on product development. The company holds an extensive patent portfolio covering its product candidates, with issued and pending patents in the United States and foreign jurisdictions including Europe, Canada, Japan, South Korea, Australia, and China.
The company's intellectual property strategy includes in-licensed patents and proprietary know-how, particularly through a licensing agreement with Vernalis for adenosine receptor antagonists. Corvus Pharmaceuticals' competitive positioning derives from its scientific and management team experience and the strength of its product candidates targeting novel immune pathways. The company's website is www.corvuspharm.com.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1626971
- SIC
- 2834
Financial performance, year by year
Fiscal 2016–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Corvus Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Corvus Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Corvus Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Corvus Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Corvus Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”